Company: BLRX
Filing Date: 2025-11-17
Form Type: 6-K
Source: 0001178913-25-003874
Chunk: 0

Company: BioLineRx Ltd.
Filing Date: 2025-11-17
Form: 6-K
Chunk 0
---
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒Form 40-F ☐ CONTENTS Attached hereto and incorporated herein is the registrant’s press release issued on November 17, 2025, titled “BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types.” EXHIBIT INDEX

| Exhibit No. |     |                                                                                                                                      |
| 99.1        |     | Press release titled:                                                                                                                
 “BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types.” |

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| BioLineRx Ltd. |                         |
| By:            | /s/ Philip A. Serlin    |
|                | Philip A. Serlin        |
|                | Chief Executive Officer |

Dated: November 17, 2025